Press Releases ARYA Sciences Acquisition Corp IV

Equities

ARYD

KYG316591083

Market Closed - Nasdaq Other stock markets 02:00:00 06/07/2024 am IST			5-day change	1st Jan Change
11.52 ^USD	0.00%		+0.44%	+5.69%

28/06	ARYA Sciences Acquisition Corp IV announced that it has received $0.15 million in funding from ARYA Sciences Holdings IV	CI
20/05	ARYA Sciences Acquisition Corp IV Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ARYA Sciences Acquisition IV : ADAGIO MEDICAL Investor Presentation \| June 2024 1 Form 8 K	12/06	PU
ARYA Sciences Acquisition IV : G220229/S002/A001 - Form 8-K	02/05	PU
ARYA Sciences Acquisition IV : Failure to Satisfy Listing Rule - Form 8-K	29/03	PU
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies	14/02	PR
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	03/23/03	PU
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	05/23/05	PU
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	03/23/03	PU
ARYA Sciences Acquisition Corp V will redeem its Class A Ordinary Shares and will not consummate an initial business combination	04/23/04	GL
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	07/23/07	AQ
ARYA Sciences Acquisition IV : Non-Reliance on Previously Issued Financial Report - Form 8-K	05/23/05	PU
ARYA SCIENCES ACQUISITION CORP IV : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	05/23/05	AQ
ARYA SCIENCES ACQUISITION CORP IV : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	02/23/02	AQ
ARYA SCIENCES ACQUISITION CORP IV : Other Events (form 8-K)	27/23/27	AQ
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/22/08	AQ
ARYA SCIENCES ACQUISITION CORP IV : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)	08/22/08	AQ
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/22/08	AQ
ARYA SCIENCES ACQUISITION IV : AND AMICUS THERAPEUTICS, INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT WITH RESPECT TO THE ACQUISITION OF AMICUS’ GENE THERAPY BUSINESS DUE TO MARKET CONDITIONS - Form 8-K	24/22/24	PU
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions	24/22/24	AQ
ARYA Sciences Acquisition IV : As discussed in Note 2 to the financial statement, the March 2, 2021 financial statement has been restated to correct a certain misstatement - Form 8-K/A	14/22/14	PU
Amicus Therapeutics : and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company, 'Caritas Therapeutics'	30/21/30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ARYA Sciences Acquisition Corp IV

Equities

ARYD

KYG316591083

Press Releases

Filters